Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

doi:10.4251/wjgo.v16.i11.4392

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (922)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

HTML

558

Figures (1-2)

Tables (1-5)

Sum=765

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=119

Nov 15, 2024 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4392-4401
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4392

Full Size Figure Download Figure

Figure 1 Selection criteria. uHCC: Unresectable hepatocellular carcinoma; C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; ECOG-PS: Eastern Cooperative Oncology Group Performance Status.

Citation: Yang H, Qiu GP, Liu J, Yang TQ. Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(11): 4392-4401
URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4392.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4392